1. Executive Summary (Confidence: High)

Ilonov, founded in 2020 as a spin-off of the European Diabetes Study Center (CeeD) in Strasbourg, is a French-Swiss biotech entity uniquely positioned at the forefront of the longevity ecosystem.^[12] The organization treats skeletal muscle as an endocrine organ, harvesting the therapeutic potential of myokines—hormones naturally secreted during exercise—to regulate systemic metabolism.^[12] Their primary mission is to alleviate the burden of daily diabetes management and eliminate severe age-related complications like renal failure.^[12] As of March 2025, Ilonov has joined the BaseLaunch portfolio and entered a research collaboration with a leading pharmaceutical partner to explore the biological mechanisms of their lead candidate, ILV-001.12 This strategic shift aims to validate the "muscle-pancreas crosstalk" as a major new therapeutic domain for chronic diseases and longevity.^[12]